Featured Research

from universities, journals, and other organizations

Common osteoporosis drug slows formation of new bone

Date:
April 17, 2013
Source:
Endocrine Society
Summary:
Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study.

Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

Related Articles


Osteoporosis weakens bones and increases the risk patients will suffer fractures. The findings suggest combination therapy may be a more effective approach to battling this common condition.

"The key to effectively treating osteoporosis lies in increasing bone mass," said the study's lead author, Antonino Catalano, MD, PhD, of the University of Messina in Italy. "Zoledronic acid halts bone loss, but it also signals the body to stop forming new bone mass. The drug may need to be combined with other treatments to add bone mass."

The prospective intervention study followed the treatment of 40 postmenopausal women at an ambulatory care center. Half of the women received zoledronic acid, and half received a placebo. Levels of sclerostin -- a biomarker that inhibits bone formation -- increased among the participants who were treated with zoledronic acid.

"The data points to an opportunity to increase bone mass by combining zoledronic acid with a drug that suppresses the resulting sclerostin's effect," Catalano said. "An innovative combination therapy using zoledronic acid and selective antibodies to block the sclerostin could simultaneously stop bone loss and encourage new bone formation. This is an important avenue for researchers to explore as they develop new osteoporosis treatments."

Other researchers working on the study include: N. Morabito, G. Basile, S. Brancatelli, D. Cucinotta and A. Lasco of the University of Messina.


Story Source:

The above story is based on materials provided by Endocrine Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Antonino Catalano, Nancy Morabito, Giorgio Basile, Santa Brancatelli, Domenico Cucinotta and Antonino Lasco. Zoledronic Acid Acutely Increases Sclerostin Serum Levels in Women with Postmenopausal Osteoporosis. Journal of Clinical Endocrinology & Metabolism, 2013 DOI: 10.1210/jc.2012-4039

Cite This Page:

Endocrine Society. "Common osteoporosis drug slows formation of new bone." ScienceDaily. ScienceDaily, 17 April 2013. <www.sciencedaily.com/releases/2013/04/130417164628.htm>.
Endocrine Society. (2013, April 17). Common osteoporosis drug slows formation of new bone. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2013/04/130417164628.htm
Endocrine Society. "Common osteoporosis drug slows formation of new bone." ScienceDaily. www.sciencedaily.com/releases/2013/04/130417164628.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins